Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

December 31, 2011

Conditions
Uterine Carcinosarcoma
Interventions
DRUG

paclitaxel

Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.

DRUG

carboplatin

Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.

DRUG

BSI-201 (Iniparib)

BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).

Trial Locations (40)

23298

Research Site, Richmond

24014

Research Site, Roanoke

27157

Research Site, Winston-Salem

28204

Research Site, Charlotte

32804

Research Site, Orlando

43235

Research Site, Columbus

46260

Research Site, Indianapolis

53792

Research Site, Madison

60612

Research Site, Chicago

63110

Research Site, St Louis

65804

Research Site, Springfield

70806

Research Site, Baton Rouge

73104

Research Site, Oklahoma City

Unknown

Research Site, Aurora

Research Site, Englewood

Research Site, New Britain

Research Site, Gainsville

Research Site, Savannah

Research Site, Chicago

Research Site, Hinsdale

Research Site, Urbana

Research Site, Scarborough

Research Site, Kalamazoo

Research Site, Brooklyn

Research Site, Buffalo

Research Site, New York

Research Site, Stony Brook

Research Site, Chapel Hill

Research Site, Charlotte

Research Site, Cleveland

Research Site, Columbus

Research Site, Mentor

Research Site, Tulsa

Research Site, Abington

Research Site, Pittsburgh

Research Site, Wynnewood

Research Site, Wyomissing

08103

Research Site, Camden

02905

Research Site, Providence

05401

Research Site, Burlington

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

Sanofi

INDUSTRY

NCT00687687 - Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma | Biotech Hunter | Biotech Hunter